As indicated in Figure 6, this strategy may increase the safety profile of the CD4 CAR-T cell product as it facilitates enhanced binding of the CAR-T cells to CD4+ tumor cells, thereby improving the chance of additional target engagement and killing of the tumor cells. Here, CD4 is linked to neoplasm.